Predictive biomarkers of recovery in traumatic brain injury

Neurocritical Care

Volumn 16, Issue 3, 2012, Pages 470-477

  Giacoppo, Sabrina ^a   Bramanti, Placido ^a   Barresi, Marina ^a   Celi, Debora ^a   Cuzzola, Valeria Foti ^a   Palella, Eleonora ^a   Marino, Silvia ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Biomarkers; Central nervous system; Cerebrospinal fluid; Outcome; Serum; Traumatic brain injury

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CREATINE KINASE BB; DNA; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PROTEIN S100B; UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

BLOOD LEVEL; BRAIN DAMAGE; CEREBROSPINAL FLUID LEVEL; DEATH; DIFFUSE AXONAL INJURY; HUMAN; INJURY SEVERITY; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRAUMATIC BRAIN INJURY; BRAIN INJURY; CONVALESCENCE; INTENSIVE CARE; METABOLISM; PHYSIOLOGY;

BIOLOGICAL MARKERS; BRAIN INJURIES; HUMANS; INTENSIVE CARE; PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION;

EID: 84873053780     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-012-9707-z     Document Type: Review

References (73)

1. Kraus J, McArthur D. Epidemiology of brain injury. In: Cooper P, Golfinos J, editors. Head injury. 4th ed. New York: McGraw-Hill Publishers; 2000. p. 1-26.
2. Pineda JA, Wang KK, Hayes RL. Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol. 2004;14(2):202-9.
3. Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia. 2003;44(Suppl 10):2-10.
4. Rutland-Brown W, Langlois JA, Thomas KE, Xi YL. Incidence of traumatic brain injury in the United States, 2003. J Head Trauma Rehabil. 2006;21(6):544-8.
5. Servadei F, Verlicchi A, Soldano F, Zanotti B, Piffer S. Descriptive epidemiology of head injury in Romagna and Trentino. Comparison between two geographically different Italian regions. Neuroepidemiology. 2002;21:297-304.
6. Chamoun RB, Gopinath SP, Robertson CS. Biomarkers for Traumatic Brain Injury. European Critical Care & Emergency Medicine. 2009;47-8.
7. Choi DW. Exploratory clinical testing of neuroscience drugs. Nat Neurosci. 2002;5(Suppl):1023-5.
8. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma. 2004;21:1553-61.
9. Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. 2004;62(8):1303-10.
10. Berger RP, Dulani T, Adelson D, Leventhal JM, Richichi R, Kochanek PM. Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics. 2006;117(2):325-32.
11. Ingebrigtsen T, Romner B. Biochemical serum markers of traumatic brain injury. J Trauma. 2002;52(4):798-808.
12. Yurgel VC, Ikut N, Da Rocha B, et al. Role of plasma DNA as a predictive marker of fatal outcomes following severe head injury in males. J Neurotrauma. 2007;24:1172-81.
13. Rodrigues E, Oliveira C, Cambrussi A, Gomes G, Godoy D, da Rocha AB, et al. Increased serum brain derived neurotrophic factor (BDNF) following isolated severe traumatic brain injury in humans. Brain Inj. 2008;22(Suppl 1):165.
14. Papa L, Akinyi L, Liu MC, Pineda JA, Tepas JJ, Oli MW, Zheng W, Robinson G, Robicsek SA, Gabrielli A, Heaton SC, Hannay HJ, Demery JA, Brophy GM, Layon J, Robertson CS, Hayes RL, Wang KK. Ubiquitin C terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med. 2010;38:138-44.
15. Mondello S, Papa L, Buki A, Bullock MR, Czeiter E, Tortella FC, Wang KK, Hayes RL. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care. 2011;15(3):R156.
16. Marino S, Zei E, Battaglini M, Vittori C, Buscalferri A, Bramanti P, Federico A, De Stefano N. Acute metabolic brain changes following traumatic brain injury and their relevance to clinical severity and outcome. J Neurol Neurosurg Psychiatry. 2007;78(5):501-7.
17. Cernak I, Vink R, Zapple DN, et al. The pathobiology of moderate diffuse traumatic brain injury as identified using a new experimental model of injury in rats. Neurobiol Dis. 2004;17:29-43.
18. Strich SJ. Shearing of nerve fibres as a cause of brain damage due to head injury. Lancet. 1961;2:444-8.
19. Adams JH, Doyle D, Graham DI, et al. Microscopic diffuse axonal injury in cases of head injury. Med Sci Law. 1985;25:265-9.
20. Marino S, Ciurleo R, Bramanti P, Federico A, De Stefano N.1H-MR spectroscopy in traumatic brain injury. Neurocrit Care. 2011;14(1):127-33.
21. Vos PE. Biomarkers of focal and diffuse traumatic brain injury. Crit Care. 2011;15(4):183.
22. Bakay RA, Ward AAJ. Enzymatic changes in serum and cerebrospinal fluid in neurological injury. J Neurosurg. 1983;58:27-37.
23. Narayan RK, Michel ME, Ansell B, Baethmann A, Biegon A, Bracken MB, Bullock MR, Choi SC, Clifton GL, Contant CF, Coplin WM, et al. Clinical trials in head injury. J Neurotrauma. 2002;19:503-57.
24. Kochanek PM, Berger RP, Bayir H, Wagner AK, Jenkins LW, Clark RS. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care. 2008;14(2):135-41.
25. Donato R. 118. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33(7):637-68.
26. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002;7:d1356-68.
27. Townend W, Ingebrigtsen T. Head injury outcome prediction: a role for protein S-100B? Injury. 2006;37(12):1098-108.
28. Donato R. Further studies on the specific interaction of S-100 protein with synaptosomal particulates. J. Neurochem. 1976;27:439-47.
29. Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, et al. Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. 2006;25(5):446-53.
30. Gazzolo D, Florio P, Zullino E, Giovannini L, Scopesi F, Bellini C, Peri V, Mezzano P, Petraglia F, Michetti F. S100B protein increases in human blood and urine during stressful activity. Clin Chem Lab Med. 2010;48(9):1363-5.
31. Routsi C, Stamataki E, Nanas S, Psachoulia C, Stathopoulos A, Koroneos A, Zervou M, Jullien G, Roussos C. Increased levels of serum S100B protein in critically ill patients without brain injury. Shock. 2006;26(1):20-4.
32. Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Mutschler W, Jochum M. Serum S-100B and inter-leukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. Crit Care Med. 2002;30(12):2669-74.
33. Korfias S, Stranjalis G, Boviatsis E, Psachoulia C, Jullien G, Gregson B, Mendelow AD, Sakas DE. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med. 2007;33(2):255-60.
34. Raabe A. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;49(6):1491-2.
35. Regner A, Kaufman M, Friedman G, Chemale I. Increased serum S100beta protein concentrations following severe head injury in humans: a biochemical marker of brain death? NeuroReport. 2001;12(4):691-4.
36. Barger SW, Van Eldik LJ, Mattson MP. S100 beta protects hippocampal neurons from damage induced by glucose deprivation. Brain Res. 1995;677(1):167-70.
37. Willoughby KA, Kleindienst A, Müller C, Chen T, Muir JK, Ellis EF. S100B protein is released by in vitro trauma and reduces delayed neuronal injury. J Neurochem. 2004;91(6):1284-91.
38. Slemmer JE, Matser EJ, De Zeeuw CI, Weber JT. Repeated mild injury causes cumulative damage to hippocampal cells. Brain. 2002;125(Pt 12):2699-709.
39. Woertgen C, Rothoerl RD, Metz C, Brawanski A. Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma. 1999;47(6):1126-30.
40. Raabe A, Grolms C, Keller M, Dohnert J, Sorge O, Seifert V. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir (Wien). 1998;140:787-791. discussion 791-792.
41. Rothermundt M, Peters SM, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003;60:614-32.
42. Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg. 2005;103:61-8.
43. Chen DQ, Zhu LL. Dynamic change of serum protein S100b and its clinical significance in patients with traumatic brain injury. Chin J Traumatol. 2005;8:245-8.
44. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma. 2004;56:1229-34.
45. Wunderlich MT, Wallesch CW, GoertlerR M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci. 2004;227:49-53.
46. Moore BW, McGregor D. Chromatographic and electrophoretic fractionation of soluble proteins of brain and liver. J Biol Chem. 1965;240:1647-53.
47. Fletcher L, Rider CC, Taylor CB. Enolase isoenzymes. III. Chromatographic and immunological characteristics of rat brain enolase. Biochim Biophys Acta. 1976;452(1):245-52.
48. Pelinka LE, Hertz H, Mauritz W, Harada N, Jafarmadar M, Albrecht M, et al. Nonspecific increase of systemic neuronspecific enolase after trauma: clinical and experimental findings. Shock. 2005;24(2):119-23.
49. Marangos PJ, Schmechel DE. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 1987;10:269-95.
50. Nygaard O, Langbakk B, Romner B. Neuron-specific enolase concentrations in serum and cerebrospinal fluid in patients with no previous history of neurological disorder. Scand J Clin Lab Invest. 1998;58(3):183-6.
51. Herrmann M, Curio N, Jost S, Grubich C, Ebert AD, Fork ML, Synowitz H. Release of biochemical markers of damage to neuronal and glial brain tissue is associated with short and long term neuropsychological outcome after traumatic brain injury. J Neurol Neurosurg Psychiatry. 2001;70(1):95-100.
52. Meynaar IA, Oudemans-van Straaten HM, van der Wetering J, Verlooy P, Slaats EH, Bosman RJ, et al. Serum neuron-specific enolase predicts outcome in post-anoxic coma: a prospective cohort study. Intensive Care Med. 2003;29(2):189-95.
53. Johnsson P. Markers of cerebral ischemia after cardiac surgery. J Cardiothorac Vasc Anesth. 1996;10(1):120-6.
54. Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol. 1995;43(3):267-70.
55. Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H, Wallesch CW. Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor Neurol Neurosci. 1999;14(2-3):109-14.
56. Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuronspecific enolase as an aid to outcome prediction in head injury. Br J Neurosurg. 1996;10:471-6.
57. Ergün R, Bostanci U, Akdemir G, Beşkonakli E, Kaptanoǧlu E, Gürsoy F, Taşkin Y. Prognostic value of serum neuron-specific enolase levels after head injury. Neurol Res. 1998;20(5):418-20.
58. Thomas DG, Palfreyman JW, Ratcliffe JG. Serum-myelin-basicprotein assay in diagnosis and prognosis of patients with head injury. Lancet. 1978;1(8056):113-5.
59. Gale SD, Johnson SC, Bigler ED, Blatter DD. Nonspecific white matter degeneration following traumatic brain injury. J Int Neuropsychol Soc. 1995;17-28.
60. Liu MC, Akle V, Zheng W, Kitlen J, O'Steen B, Larner SF, Dave JR, Tortella FC, Hayes RL, Wang KK. Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J Neurochem. 2006;98(3):700-12.
61. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 2000;31(11):2670-7.
62. Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999;45:138-41.
63. Nylén K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgård B, Rosengren L. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci. 2006;240(1-2):85-91. Epub 2005 Nov 2.
64. Coplin WM, Longstreth WT Jr, Lam AM, Chandler WL, Mayberg TS, Fine JS, Winn HR. Cerebrospinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage. Arch Neurol. 1999;56(11):1348-52.
65. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem. 2000;46(3):319-23.
66. Lam NY, Rainer TH, Chan LY, Joynt GM, Lo YM. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem. 2003;49(8):1286-91.
67. Rainer TH, Wong LK, Lam W, Yuen E, Lam NY, Metreweli C, Lo YM. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem. 2003;49(4):562-9.
68. McAllister AK, Katz LC, Lo DC. Neurotrophins and synaptic plasticity. Annu Rev Neurosci. 1999;22:295-318.
69. Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD. From acquisition to consolidation: on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem. 2002;9:224-37.
70. Riley CP, Cope TC, Buck CR. CNS neurotrophins are biologically active and expressed by multiple cell types. J Mol Histol. 2004;35:771-83.
71. Saha RN, Liu X, Pahan K. Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol. 2006;1(3):212-22.
72. Griesbach GS, Hovda DA, Gomez-Pinilla F, Sutton RL. Voluntary exercise or amphetamine trwatment, but not the combination, increases hippocampal brain-derived neurotrophic factor and synapsin I following cortical contusion injury in rats. Neurosciences. 2008;154(2):530-40.
73. Jackson P, Thompson RJ. The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci. 1981;49:429-38.